DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Liver fibrosis stage determines which GLP-1 is FDA-indicated and most effective. Wegovy received the first formal MASH approval in March 2026 for F2-F3. Pick your stage to see ranked options.
March 2026: First FDA-approved GLP-1 for MASH
Wegovy 2.4mg approval for F2-F3 non-cirrhotic MASH, based on ESSENCE trial. 37% achieved ≥1 stage fibrosis improvement vs 22% on placebo over 72 weeks. This marks the start of formal liver-disease GLP-1 indications — SYNERGY-NASH (tirzepatide) readout pending Q4 2026.
Select your fibrosis stage
Not sure of your stage? FibroScan or transient elastography report from your hepatologist gives F0-F4. MRI elastography is most accurate. Liver biopsy is the gold standard.
Bridging fibrosis. The first FDA-indicated stage for Wegovy MASH treatment (March 2026). Annual liver biopsy or FibroScan monitoring required.
FDA status: Wegovy 2.4mg FDA-approved for F2-F3 non-cirrhotic MASH (March 2026, based on ESSENCE trial). Primary endpoint: fibrosis improvement ≥1 stage without MASH worsening.
F2 is the first formally-indicated MASH stage for GLP-1 treatment. Wegovy is the labeled choice.
FDA-indicated for F2 MASH (March 2026). ESSENCE trial: 37% achieved ≥1 stage fibrosis improvement vs 22% placebo.
Off-label but increasingly used for F2 MASH given higher weight-loss efficacy.
Caveat: SYNERGY-NASH readout will determine formal indication. Until then, Wegovy is the labeled choice.
Oral tirzepatide. Same mechanism as Zepbound. Useful if injection avoidance is priority.
Caveat: No MASH-specific data yet — Apr 2026 launch.
MASH (metabolic dysfunction-associated steatohepatitis) is the inflammatory form of fatty liver disease — previously called NASH. The broader category MASLD (formerly NAFLD) includes simple steatosis without inflammation. MASH carries the fibrosis progression risk.
Wegovy 2.4mg received FDA approval for F2-F3 non-cirrhotic MASH in March 2026, based on the ESSENCE trial. This is the first GLP-1 indication specifically for liver disease. Other GLP-1s show benefit but aren't formally indicated yet.
FibroScan (transient elastography) is the most common non-invasive test — your hepatologist or gastroenterologist orders it. MRI elastography is more accurate but expensive. Liver biopsy remains the gold standard but is invasive. Many primary care clinicians can interpret a FibroScan result.
Yes — ESSENCE trial showed 37% of patients on Wegovy achieved ≥1 stage fibrosis improvement vs 22% on placebo, over 72 weeks. Earlier stages (F1-F2) show higher reversal rates than later (F3).
F4 cirrhosis was excluded from major GLP-1 trials. Decompensated cirrhosis (Child-Pugh B/C) is generally a contraindication. Compensated cirrhosis (Child-Pugh A) may allow GLP-1 use under hepatology specialist management, but this is highly individualized.
Staging guidance reflects ESSENCE trial data + AASLD 2024 MASH treatment guidelines. Always coordinate GLP-1 initiation with your hepatologist or gastroenterologist if you have F2+ fibrosis.
Wegovy review →·GLP-1 by kidney function (CKD)·Our methodology